FDA approves MSD’s Lipfendra as first oral PCSK9 inhibitor
FDA approves MSD’s Lipfendra as first oral PCSK9 inhibitor European Pharmaceutical Review
Finance, IT & News
FDA approves MSD’s Lipfendra as first oral PCSK9 inhibitor European Pharmaceutical Review
FDA clears Taylor Farms as cyclospora source; Louisiana case count reaches 55 KNOE
BioMarin Advances VOXZOGO Toward Full FDA Approval Streetwise Reports
Citizens reiterates Artivion stock rating citing FDA approval benefits Investing.com
Behind the FDA Approval: Isatuximab On-Body Injector Supports ‘Patient-Centric’ Priorities in Multiple Myeloma Targeted Oncology